Faron Pharmaceuticals Oy's (LON:FARN) chief executive Dr Markku Jalkanen tells Proactive London's Andrew Scott its drug Traumakine has been admitted to a large-scale global programme that will assess its potential in treating severe pneumonia. The study also includes patients suffering from the latest virus outbreak.
The formulation will be delivered intravenously, which he says offers the best “delivery route” for critically ill patients.
0 Comments